Fig. 7
The safety and efficacy of the attenuated vaccine candidate MHVoctm with modified vaccination strategy. (A) Timeline and experimental groups for examination of the efficacy and safety of the attenuated vaccine MHVoctm. The reduced dosages (106, 104 and 102 pfu) of MHVoctm and one vaccination were used for the experiment. (B)-(F) Examination of body weight (B), clinical score (C), survival rate (D), synthesis of viral RNA (E) and pathological changes in which coagulation necrosis and vacuolated hepatocytes (ballooning degeneration) were observed in the livers of mice inoculated with DMEM but not with MHVoctm after challenge with MHVwt (scale bar = 100 μm) (F). dpc, days postchallenge; MHVwt, wild-type MHV; MHVoctm, MHV with octamer mutation. Statistical significance was evaluated using a t test: * P < 0.05